20th Jan 2014 08:37
LONDON (Alliance News) - Shares in EKF Diagnostics Holdings PLC were trading up 12% Monday morning after it reported positive test results using its PointMan technology to analyse blood in cancer patients to identify gene mutations associated with a response to treatment.
In a test in collaboration with the Institute of Life Sciences at Swansea University, the technology was used to identify mutations in the gene BRAF in blood samples archived in the Wales Cancer Bank.
"This is a major step forward not just for the company but also for the future testing of cancer patients, where we hope that less-invasive testing will become routine using our Pointman technology," said Chief Executive Officer Julian Baines in a statement.
Shares in EKF were trading up 12% at 39.55 pence Monday morning, after spiking to 43.00 pence at the open.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Ekf Diagnostics